造影增強(qiáng)eus與胰腺疾病診治

1、造影增強(qiáng)內(nèi)鏡超聲在胰腺疾病診治中的作用,孫金山,造影增強(qiáng)超聲的發(fā)展,靜脈造影劑最早用于心血管疾病超聲檢查，以增強(qiáng)心腔及大血管的超聲顯像Keller MW, Feinstein SB, Watson DD. Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: an exp

2、erimental evaluation. Am Heart J 1987; 114: 570-575此后，該項(xiàng)技術(shù)在經(jīng)腹超聲及內(nèi)鏡超聲領(lǐng)域快速發(fā)展Goldberg BB, Hilpert PL, Burns PN, Liu JB, Newman LM, Merton DA, Witlin LA. Hepatic tumors: signal enhancement at Doppler US after intravenous i

3、njection of a contrast agent. Radiology 1990; 177: 713-717Bhutani MS, Hoffman BJ, van Velse A, Hawes RH. Contrast-enhanced endoscopic ultrasonography with galactose microparticles: SHU508 A (Levovist). Endoscopy 1997;29

4、:635-639,靜脈造影劑的類型及組成,,胰腺疾病常規(guī)EUS的優(yōu)勢(shì)與不足,優(yōu)勢(shì)更接近病變，能夠更好地顯示病變的組織結(jié)構(gòu)及病變與周圍臟器和血管的關(guān)系經(jīng)EUS-FNA獲取細(xì)胞/組織/囊液對(duì)病變的診斷、腫瘤分級(jí)/分期、術(shù)前定位等可能優(yōu)于CT/MRI不足對(duì)腫瘤血管等顯示欠佳對(duì)一些形態(tài)相近病變，如腫塊型胰腺炎vs胰腺癌vs胰腺神經(jīng)內(nèi)分泌腫瘤、多種胰腺囊性病變等，診斷及良惡性鑒別存在困難,CE-EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰

5、腺炎與胰腺癌（PDAC）的鑒別,D Becker,et al. Gastrointest Endosc,2001,CE-EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰腺炎與胰腺癌（PDAC）的鑒別,D Becker,et al. Gastrointest Endosc,2001,CE-EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰腺炎與胰腺癌（PDAC）的鑒別,Gheonea et al. BMC Gastroenterology，2013,CE-

6、EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰腺炎與胰腺癌（PDAC）的鑒別,Gheonea et al. BMC Gastroenterology，2013,CE-EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰腺炎與胰腺癌（PDAC）的鑒別,Gheonea et al. BMC Gastroenterology，2013,CE-EUS在胰腺疾病診治中的應(yīng)用,㈠腫塊型胰腺炎與胰腺癌的鑒別Results：sensitivity and specif

7、icity of low MI contrast enhanced EUS using TIC analysis were 93.75% (95% CI = 77.77-98.91%) and 89.47% (95% CI = 65.46-98.15%), respectively. The positive predictive value of TIC analysis was 93.75% (95% CI = 77.78-98.9